One of the biggest problems with Alzheimer's is late diagnosis. When a patient is diagnosed, the damage is already progressing. A new study in Nature Communications presents the news: Two proteins in the spinal fluid that can predict 3 years in advance who will go from MCI to dementia.
The proteins: NPTX1 and NPTXR
NPTX1 and NPTXR (Neuronal Pentraxin) are proteins whose role is to maintain the synapses. When their levels drop in the cerebrospinal fluid (CSF), it is a sign that the synapses are breaking down, the first sign of Alzheimer's.
The study
An international team recruited 635 participants in China and Norway. They were measured in NPTX and also in established markers: pTau181, Neurofilament Light Chain.
The main findings
- Correlation with disease grade: NPTX levels decrease linearly with Alzheimer's progression
- Correlation with MRI damage: Cortical thickening in Alzheimer-vulnerable areas
- 3-year prediction: Low levels at baseline predict progression to dementia within 3 years
- Superior to existing markers: NPTX was 15-20% better predictor than pTau181 alone
Why does it matter?
New drugs like lecanemab cost $70,000 a year and come with side effects. NPTX can filter: treat only those who will deteriorate, not those who will be stable.
What does this mean about you?
If you have memory complaints over age 60 or a family history of Alzheimer's, ask your neurologist about a comprehensive CSF test. Currently pTau181 + Neurofilament are available. NPTX will join soon.
The bottom line
One test can predict three years ahead. This is the critical time available. Early intervention = better results.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.